Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: A comparison of Indonesian, Chinese, and European subjects

Journal of Infectious Diseases

Volumn 190, Issue 1, 2004, Pages 53-62

  Fachiroh, Jajah ^a   Schouten, Tabitha ^c   Hariwiyanto, Bambang ^a   Paramita, Dewi K ^a   Harijadi, Ahmad ^a   Haryana, Sofia M ^a   Ng, Mun H ^b   Middeldorp, Jaap M ^c  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; THYMIDINE KINASE; VIRUS CAPSID ANTIGEN; VIRUS PROTEIN;

ANTIGEN FUNCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SAMPLE; SERUM; VIRUS INFECTION;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; CAPSID PROTEINS; CARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HERPESVIRUS 4, HUMAN; HONG KONG; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INDONESIA; NASOPHARYNGEAL NEOPLASMS; VARIATION (GENETICS);

EID: 3042810186     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/421245     Document Type: Article

References (48)

1. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35:35-42.
2. Rickinson B, Kieff E. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Vol 2, 3rd ed. Philadelphia: Lippincott-Raven, 1996:2397-476.
3. Sixbey JW, Lemon SM, Pagano JS. A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet 1986; 2:1122-4.
4. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000; 53:255-61.
5. Meijer CJ, Jiwa NM, Dukers DF, et al. Epstein-Barr virus and human T-cell lymphomas. Semin Cancer Biol 1996; 7:191-6.
6. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. In: Goedert JJ, ed. Infectious causes of cancer target for intervention. Totawa, NJ: Humana Press, 2000:93-111.
7. Middeldorp JM, Brink AATP, van den Brule AJC, Meijer CJLM. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 2003; 45:1-36.
8. Henle G, Henle W. Epstein-Barr Virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17:1-7.
9. de The G. Epidemiology of Epstein-Barr virus and associated diseases. In: Roizmann B, ed. The herpesviruses. New York: Plenum Press, 1982: 25-87.
10. Ho JHC. Epidemiology of nasopharyngeal carcinoma (NPC). In: Ablashi DV, Hunad AT, Pagano, JS, Pearson GR, Yang CS, eds. Epstein-Barr virus and human disease. Totowa, NJ: Humana Press, 1990:xii-xiv.
11. Soeripto. Epidemiology of nasopharyngeal carcinoma. Berita Kedokteran Masyarakat (Ina) 1998; XIII:207-211.
12. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. In: Goedert, J, ed. Infectious causes of cancer: target for intervention. Totowa, NJ: Humana Press, 2000:93-111.
13. Baskies, AM, Chretien PB, Yan CS, et al. Serum glycoprotein and immunoglobulins in nasopharyngeal carcinoma: correlation with Epstein-Barr virus associated antibodies and clinical tumor stage. Am J Surg 1979; 138:478-88.
14. Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou city, China. Int J Cancer 1982; 29:139-41.
15. Chien YC, Chien JY, Liu MY, et al. Serological markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345:1877-82.
16. Yip TCT, Ngan RKC, Lau WH, et al. A possible prognostic role of immunoglobulin-A antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 1994; 74:2414-24.
17. Luka J, Chase RC, Pearson GR. A sensitive enzyme-linked immunosorbent assay (ELISA) against the major EBV-associated antigens I correlation between ELISA and immunofluorescence titers using purified antigens. J Immunol Methods 1984; 67:145-56.
18. Farber I, Hindere W, Rothe M, Lang D, Sonneborn HH, Wutzler P. Serological diagnosis of Epstein-Barr virus infection by novel ELISAs based on recombinant capsid antigens p23 and p18. J Med Virol 2001; 63:271-6.
19. Levine PH, Connelly RR, Milman G, Easton J. Epstein-Barr serology in the control of nasopharyngeal carcinoma. Cancer Detect Prev 1988; 12:357-62.
20. Connolly Y, Littler E, Sun N, et al. Antibodies to Epstein-Barr virus thymidine kinase: a characteristic marker for the serology detection of nasopharyngeal carcinoma. Int J Cancer 2001; 91:692-7.
21. Middeldorp JM, Herbrink P. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Methods 1988; 21:133-46.
22. van Grunsven WM, Nabbe A, Middeldorp JM. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J Med Virol 1993; 40:161-9.
23. Meij P, Vervoort MB, Aarbiou J, et al. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 1999; 179:1108-15.
24. Tedeschi R, Foong YT, Cheng HM, et al. The disease association of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol 1995; 76:1393-100.
25. Cheng, YC, Chen JY, Glaser R, Henle W Frequency and levels of antibodies to Epstein-Barr virus specific DNAse are elevated in patients with nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1980; 77:6162-5.
26. Bardy B, Morinet F, Perol Y. Occurrence of Epstein-Barr virus deoxyribonuclease enzyme activity-neutralizing antibodies. Intervirology 1989; 30: 36-43.
27. Stolzenberg MC, Debouze S, Ng M, et al. Purified recombinant EBV deoxyribonuclease in serological diagnosis of nasopharyngeal carcinoma. Int J Cancer 1996; 66:337-41.
28. Shimakage M, Ikegaman N, Chatani M, Yoshino K, Sato T. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy. Biken J 1987; 30:45-52.
29. Foong YT, Cheng HM, Sam CK, Dillner J, Hinderer W, Prasad U. Serum and salivary IgA against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 1990; 45:1061-4.
30. Dardari R, Hinderer W, Lang D, et al. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigen p54 and p138. J Clin Microbiol 2001; 39:3164-70.
31. Chan KH, Gu YL, Ng F, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 2003; 105:706-9.
32. Chen MR, Middeldorp JM, Hayward SD. Separation of the complex DNA binding domain of EBNA1 into DNA recognition and dimerization subunit of novel structure. J Virol 1993; 67:4875-85.
33. Meij P, Vervoort MBHJ, Meijer CJLM, Bloemena E, Middeldorp JM. Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells. J Virol Methods 2000; 90:193-204.
34. Zeng Y, Middeldorp JM, Madjar JJ, Ooka T. A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 1997; 239:285-95.
35. Meij P, Vervoort MB, Gooijer K, Bloemena E, Meijer CJ, Middeldorp JM. Bioreactor-scale production and one-step purification of Epstein-Barr nuclear antigen-1 expressed in baculovirus-infected insect cells. Protein Expr Purif 2000; 20:324-33.
36. Zhang JZ, Chen HL, Zong YS, et al. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 1998; 55: 227-33.
37. Rowe M, Finke J, Szigeti R, Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigen encoded by Epstein-Barr virus. J Gen Virol 1988; 69:1217-28.
38. van Grunsven WM, van Heerde EC, de Haard HJ, Spaan WJ, Middeldorp JM. Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. J Virol 1993; 67:3908-16.
39. van Grunsven WM, Spaan WJ, Middeldorp JM. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis 1994; 170:13-9.
40. Gartner B, Johannes MF, Roemer K, Mak M, Fleurent B, Mueller-Lantzsch N. Evaluation of a recombinant line blot for diagnosis of Epstein-Barr virus compared with ELISA using immunofluorescence as reference. J Virol Methods 2001; 93:89-96.
41. Henle G, Henle W, Horowitz, CA. Infectious mononucleosis and Epstein-Barr: virus-associated malignancies. In: Lenette EH, Schmidts NJ, eds. Diagnostic procedures for viral, rickettsia, and chlamidial infections. 5th ed. Washington, DC: American Public Health Association, 1979:441-65.
42. Deng H, Zeng Y, Lei Y, et al. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J (Engl) 1995; 108:300-3.
43. Murphy BR. Mucosal immunity to viruses. In: Pearay L, Ogra PL, Lamm ME, McGhee J, Mestecky J, Strober W, Bienenstock J, eds. Handbook of mucosal immunology. New York: Academic Press, 1994:333-9.
44. Motz M, Fan J, Seibl R, Jilg, W, Wolf H. Expression of the Epstein-Barr virus 138-kDa early protein in Escherichia coli for the use as antigen in diagnosis tests. Gene 1986; 42:303-12.
45. Joab I, Nicolas JC, Schwaab G, et al. Detection of anti-Epstein-Barr- virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 1991; 48:647-9.
46. Meij P, Vervoort MBHJ, Bloemena E, et al. Antibody responses to Epstein-Barr virus encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol 2002; 68:370-7.
47. Nicholls J, Kremmer E, Meseda CA, et al. Comparative analysis of the expression of the Epstein-Barr virus (EBV) anti-apoptotic gene BHRF1 in nasopharyngeal carcinoma and EBV-related lymphoid diseases. J Med Virol 2001; 65:105-13.
48. Lennette ET, Winberg G, Yadav M, Enblad G, Klein G. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer 1995; 31A: 1875-8.